KISSEI

  • Link
  • Japanese Page

Change Font Size

  • normal
  • large
  • About Kissei
  • Research & Development
  • News Release
  • Investor Relations

About Kissei

Research & Development

News Release

Investor Relations

kissei

  • About Kissei
  • Research & Development
  • News Release
  • Investor Relations
  • Link
  • Japanese Page
  • English
  • Message
  • Company Profile
  • Our Business
  • KISSEI's History
  • CSR:Environmental Initiatives
  • CSR:Social Contribution Activities
  • CSR:Consideration for Employees
  • About R&D
  • Central Research Laboratories
  • Toxicological Laboratories
  • Joetsu Chemical Laboratories
  • Pharmaceutical Laboratories
  • R&D Pipeline
  • Financial Summary
  • Annual Report
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • Message
  • Company Profile
  • Our Business
  • KISSEI's History
  • CSR:Environmental Initiatives
  • CSR:Social Contribution Activities
  • CSR:Consideration for Employees
  • About R&D
  • Central Research Laboratories
  • Toxicological Laboratories
  • Joetsu Chemical Laboratories
  • Pharmaceutical Laboratories
  • R&D Pipeline
  • Financial Summary
  • Annual Report
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • Looking Towards Tomorrow’s Health

    About Kissei

    What’s new

    More
    • February 1, 2021

      The Third Quarter of FY2020 (April 2020- December 2020)
    • February 1, 2021

      R&D Pipeline as of February 2021
    • November 13, 2020

      Annual Report 2020
    • November 5, 2020

      The Second Quarter of FY2020 (April 2020 - September 2020)
    • August 3, 2020

      The First Quarter of FY2020 (April 2020 - June 2020)

    News Release

    More
    • March 24, 2021

      Participation in global Phase III clinical trial for CG0070, a drug for bladder cancer
    • March 1, 2021

      Submission of New Drug Application for Avacopan (CCX168), a Complement C5a Receptor Inhibitor, in Japan
    • January 13, 2021

      Results of Phase III Clinical Study of AJM300 (Nonproprietary Name: Carotegrast Methyl) for Treatment of Ulcerative Colitis Conducted in Japan (AJM300/CT3 Study) - Primary Endpoint Achieved -
    • December 10, 2020

      The Efficacy and Safety Results of the Overseas Phase-III Long-Term Study of Uterine Fibroids for GnRH Antagonist, Linzagolix, conducted by ObsEva
    • November 24, 2020

      Submission of Marketing Authorization Application to the European Medicines Agency for Linzagolix for the treatment of uterine fibroids
    • About Kissei

    • Research &
      Development

    • Investor Relations

    • About Kissei
    • Research & Development
    • News Release
    • Investor Relations
    • Privacy Policy
    © 2012- Kissei Pharmaceutical Co., Ltd. All rights reserved.
    キッセイ薬品工業株式会社